Treatment interruption in children with HIV infection

Current Opinion in HIV and AIDS

Volumn 2, Issue 1, 2007, Pages 62-68

  Green, Hannah ^a   Gibb, Diana M ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

CD4; Paediatric; Planned structured treatment interruptions

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CARDIOTOXICITY; CHILD CARE; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID METABOLISM; LIPODYSTROPHY; OBSERVATIONAL STUDY; OSTEOPOROSIS; PEDIATRICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 34250665047     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328011aac4     Document Type: Review

References (26)

1. Steinman GG. Changes in human thymus during aging. Curr Topics Pathol 1986; 75:43-88.
2. Walker AS, Doerholt K, Sharland M, Gibb DM, for the Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18:1915-1924.
3. Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviraltherapy in pretreated, vertically HIV type-1 infected children: 6 years of follow-up. Clin Infect Dis 2006; 42:862-869.
4. Soh CH, Oleske JM, Brady MT, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1 infected children and adolescents. Lancet 2003; 362:2045-2051.
5. De Rossi A, Walker AS, Klein N, et al. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis 2002; 186:312-320.
6. Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 1994; 13:2359-2367.
7. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997; 336:1337-1342.
8. HIV Paediatric Prognostic Markers Collaborative Study Group. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006; 20:1289-1294. This paper suggests that the relationship between absolute CD4 count and short-term risk of disease progression in HIV-1-infected children as young as 4 or 5 years is similar to that seen in adults.
9. HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1 infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362:1605-1611.
10. Vigano A, Thorne C for the Italian Register on HIV in Children, European Collaborative Study. Fat redistribution and metabolic abnormalities in HIV-infected children and adolescents in Europe. In: 10th Conference on Retroviruses and Opportunistic Infections; February 2003; Boston, MA, USA. Abstract 774.
11. Luzuriaga K, Sullivan JL. Viral and immunopathogenesis of vertival HIV-1 infection. In: Pizzo P, Wilfert C, editors. Pediatric AIDS: the challenge of HIV infection in infants, children and adolescents. 3rd ed. Baltimore, MD: Williams and Wilkins; 1998.
12. Paediatric European Network for Treatment of AIDS (PENTA). 72-week follow-up of HAART started in infants aged less than 3 months: CD4, viral load and drug resistance outcomes in the PENTA 7 Study. AIDS 2004; 18:237-245.
13. Gibb DM, Duong T, Leclezio VA, et al., on behalf of the Children's Collaborative HIV Paediatric Study (CHIPS) and Sophia Children's Hospital, Rotterdam, The Netherlands. Immunological changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 (HIV-1) infection. Pediatr Infect Dis J 2004; 23:446-450.
14. CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58.
15. Borkowsky W, McFarland E, Yogev R, et al. The Pediatric AIDS Clinical Trials Group 1015 Team. In: 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, CO, USA. Abstract 9.
16. Fortuny C, Noguera A, Marco M. Treatment interruption in HIV infected children on first line HAART regimens and undetectable viral load. In: 10th European AIDS Conference; November 2005; Dublin. Abstract PE15. 2/10.
17. Ramos JT, Drummond T, Garrido-Lestache E, et al. Outcome of antiretroviral treatment interruptions in HIV infected children. In: 10th European AIDS Conference; November 2005; Dublin. Abstract PE15.2/5.
18. Bobat R, Kiepiela P, Kindra G, et al. The use of viral load versus CD4 counts in guiding therapeutic treatment interruptions in children with chronic HIV-1 infection from Durban, South Africa. In: XVI International AIDS Conference; August 2006; Toronto. Abstract CDB0532.
19. Lallemant M, Burger D, Lyall H, et al., on behalf of PENTA 11. Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA 11 (TICCH) trial. In: XVI International AIDS Conference; August 2006; Toronto. Abstract MOPE0206.
20. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared to continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465.
21. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989.
22. Wafaa E, Neaton J. The SMART Study Investigators. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. In: 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, CO, USA. Abstract 106LB.
23. Marchou B, Tangre P, Charreau I, et al. Structured treatment interruptions in HIV-infected patients with high CD4 cell counts and virologic suppression: results of a prospective, randomized, open-label trial (Window - ANRS 106). In: 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, CO. Abstract 104.
24. Palmisano L, Giuliano M, Bucciardini R, et al. Final results of a randomized, controlled trial of structured treatment interruptions vs continuous HAART in chronic HIV-infected subjects with persistent suppression of viral replication. In: 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, CI, USA. Abstract 103.
25. Hakim J, on behalf of the DART Trial Team. A structured treatment interruption (STI) strategy of 12 week cycles on and off ART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomisation within the DART trial. In: XVI International AIDS Conference; August 2006; Toronto. Abstract THLB0207.
26. WHO. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings, towards universal access: recommendations for a public health approach; February 2006.